Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 2996609 trials

Cellid Co., Ltd.

Official website

KOSDAQ-listed biopharma developing the BVAC cancer immunotherapy vaccine series and the AdCLD-CoV19-1 COVID-19 vaccine.

As of 2026-10-10, Cellid Co., Ltd. has 18 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2006 and listed on KOSDAQ in 2019, Cellid is a biopharmaceutical company specializing in cancer immunotherapy vaccines and infectious disease preventive vaccines. Using its proprietary platforms CeliVax (cancer immunotherapy vaccine) and Ad5/35 (adenovirus vector preventive vaccine), it holds a pipeline including BVAC-C, BVAC-E6E7 for head and neck cancer (Phase 1/2a approved November 2024), the COVID-19 vaccine AdCLD-CoV19-1, the Omicron-targeting AdCLD-CoV19-1 OMI (Phase 3 ongoing), and the variant-targeting AdCLD-CoV19-1 LP.8.1. It completed a GMP center in November 2020 and signed its first CMO/CDMO contract manufacturing agreement in September 2022; its R&D spending over the last three years was KRW 12.0 billion in 2023, KRW 18.2 billion in 2024, and KRW 14.6 billion in 2025, and in May 2024 it completed a small-scale merger with Fobaker Co., Ltd., launching an e-commerce business for online food distribution.

Clinical trials

data.go.kr

9 MFDS clinical trial authorisations · 2016–2024 (Phase 1/2a 3 · Phase 1 3 · Phase 3 1 · Phase 1/2 1 · Phase 2b 1)

  • Phase 1/2aBVAC-E6E72024-11-19

    2 trial sites

  • Phase 3AdCLD-CoV19-1 OMI2023-07-21

    14 trial sites

  • Phase 1/2AdCLD-CoV19-1 OMI2022-08-04

    10 trial sites

  • Phase 2bAdCLD-CoV19/ AdCLD-CoV19-12022-01-27

    7 trial sites

  • Phase 1AdCLD-CoV19/ AdCLD-CoV19-12021-07-23

    7 trial sites

  • Phase 1/2aAdCLD-CoV19/ AdCLD-CoV19-12020-12-04

    7 trial sites

  • Phase 1전립선특이적세포막항원과 전립선산탈인산화효소의 융합 암항원을 발현하도록 만들어진 PAPS 재조합유전자를 포함한 항암면역치료백신(BVAC-P)2020-03-24
  • Phase 1인간상피성장인자수용체2를 재조합하여 만들어진 HER2K1117 재조합유전자를 포함한 항암면역치료백신(BVAC-B)2018-01-23

    1 trial site

  • Phase 1/2a인유두종바이러스 항원 재조합유전자를 포함한 세포기반 항암 면역치료백신(BVAC-C)2016-04-29

    6 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

BVAC-C · 임상 2a상(면역관문억제제 병용임상 진행중) · Complete response observed in some patients; based on CeliVax platform

BVAC-E6E7 · 두경부암 · 임상 1/2a상(2024.11.19 IND 승인, 대상자 모집 시작) · Uses same cancer antigen as BVAC-C with an improved adenoviral vector

AdCLD-CoV19-1 · COVID-19 · 임상 1/2a상 완료 · Scalable manufacturing; safety and immunogenicity data secured

AdCLD-CoV19-1 OMI · 오미크론 변이 코로나19 · 임상 1/2상 완료, 임상 3상 진행(2023.07.21 식약처 승인) · All subjects dosed; data analysis underway

AdCLD-CoV19-1 LP.8.1 · LP.8.1 변이주 코로나19 · 개발중 · Targets the WHO/EMA/FDA-recommended 2025/26 variant strain

Key disclosures

KRX KIND via OpenDART
Show 11 more events

Publications

PubMed · affiliation-matched
Show 8 more publications

Patents

KIPRIS · applicant-matched
Show 42 more patents

AI reads

MAA server logs · IP-verified
57
Times AI engines pulled Cellid Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

56
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

11
live 0
Last 7 days
45
live 1
Last 30 days
57
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot48
  • GoogleGoogleOther5
  • AnthropicClaudeBot2
  • PerplexityPerplexityBot1

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 8, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Cellid Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · products · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition